Alex Zhang, Ph.D.

Managing Director

LifeSpan BioLabs

Alex Zhang, Ph.D.

Dr. Zhang is Managing Director of Lifespan BioLabs, a life science accelerator and investor based in San Francisco Bay Area. He was the Chief Scientific Officer of Hanhai Holdings Group, and the CEO of Hanhai Silicon Valley, Inc., an early-stage investor and cross-border incubator for life sciences and frontier tech startups based in San Francisco Bay Area. Prior to Hanhai, Alex was the Co-founder and Managing Partner of Enverest, LLC., a Silicon Valley based innovation solutions and investment advisory firm, with branch offices in China and Singapore. Prior to founding Enverest, Dr. Zhang spent over four years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion dollar acquisitions in IVD and MedTech areas. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Over the past decade, Dr. Zhang has been advising a number of successful biotech, MedTech and digital health startups and VC firms based in Silicon Valley, including establishing and seed-funding of an iPSC cell therapy startup. Dr. Zhang is a Board Member of the Chinese America BioPharmaceutical Society (CABS), a highly influential association with more than 4000 members and subscribers in the life sciences industry. He served a number of leadership roles in the Executive Council of CABS, including as the President in 2017-18. CABS is the largest and most active Chinese biopharmaceutical association in Northern America. Dr. Zhang was the Chair of the Organization Committee for 2017 BioPacific Conference and 2018 CABS Investor Forum. Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of 17 peer reviewed articles and 4 patents.